12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

OPB-31121: Phase I data

Otsuka and colleagues reported data from an open-label, dose-escalation, Korean Phase I trial in 30 patients with advanced solid tumors showing that OPB-31121 does not have "potential as a therapeutic option for most malignancies." There were no objective...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >